Doctors Note Logo

Published on: 9/24/2026

What treatment is approved for fibrodysplasia ossificans progressiva?

Palovarotene (brand name Sohonos) is the first and only treatment approved by the FDA for fibrodysplasia ossificans progressiva, an ultra-rare genetic condition in which bone forms in muscles, tendons, and ligaments. This oral retinoid is approved to reduce new abnormal bone growth (heterotopic ossification) in females 8 years and older and males 10 years and older, and it carries important safety warnings, including growth plate closure in growing children. Beyond approved therapy, care typically focuses on short courses of corticosteroids at the start of flare-ups, fall prevention, avoiding intramuscular injections and biopsies, and monitoring breathing and jaw function. Other drugs, such as garetosmab, remain investigational and are not yet approved. There are several important factors to consider, including eligibility, dosing, and side effects, so see below to understand more.

If you or someone you love is dealing with unexplained swelling, stiffening joints, or lumps that seem to harden over time, the details matter, and waiting rarely makes answers clearer. A free, instant, online symptom check can help you organize what you are experiencing, surface possible explanations worth discussing, and point you toward the right type of specialist. It takes only a few minutes, requires no insurance or appointment, and gives you a clearer starting point for your next conversation with a clinician.

Last reviewed for medical accuracy: 09/24/2025

answer background

Explanation

Approved Fibrodysplasia Ossificans Progressiva Treatment

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic condition where muscle and connective tissue gradually turn into bone. This “second skeleton” severely limits movement, affects daily life, and can lead to complications such as respiratory problems. Until recently, treatment options focused mainly on managing symptoms and slowing flare-ups. Today, patients and families have a landmark therapy that directly targets the disease process.

The Only Approved Therapy: Palovarotene

Palovarotene is the first—and currently the only—medication approved by health authorities specifically for fibrodysplasia ossificans progressiva treatment. Here’s what you need to know:

  • Mechanism of action
    Palovarotene is a retinoic acid receptor gamma (RARγ) agonist. It works by regulating bone growth signals, helping prevent the abnormal ossification that defines FOP.
  • Regulatory approval
    • U.S. Food and Drug Administration (FDA) approval for patients aged 14 and older to reduce new heterotopic (extra-skeletal) bone formation.
    • Similar approvals in other regions based on clinical trial data showing reduced flare-up frequency and less new bone growth.
  • Dosing and administration
    • Typically taken once daily by mouth, with or without food.
    • Dosage varies by age and body weight; strict adherence to your doctor’s prescription is essential.
    • Regular monitoring recommended to track liver function and other safety parameters.
  • Benefits and risks
    • Clinical trials demonstrated fewer and less severe flare-ups, preserving joint mobility.
    • Common side effects include dry skin, itching, hair thinning, and mild liver enzyme elevations.
    • Rare but serious risks such as elevated triglycerides or vision changes require prompt medical review.

Supportive and Symptom-Based Management

Even with palovarotene, comprehensive care remains critical. Supportive treatments help manage flare-ups and maintain function:

• Acute flare-up care

  • High-dose corticosteroids (for example, prednisone) started within 24 hours of a new lump to reduce inflammation.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen to ease pain.
  • Short courses only—long-term steroid use has its own risks.

• Pain relief and muscle relaxation

  • Analgesics (acetaminophen or NSAIDs) for mild to moderate discomfort.
  • Muscle relaxants (such as cyclobenzaprine) for spasms, under physician guidance.

• Physical therapy and activity

  • Gentle, range-of-motion exercises prevent joint stiffness without triggering new bone formation.
  • Avoid aggressive stretching or high-impact activities.
  • A physical therapist experienced with FOP can tailor a safe exercise plan.

• Respiratory and nutritional support

  • Deep-breathing exercises and regular monitoring of lung function.
  • Nutritional counseling to maintain healthy weight and support immune function.

• Surgical interventions

  • Surgery to remove extra bone is generally discouraged: new bone almost always forms back, often faster and in greater volume.
  • If surgery is absolutely necessary (e.g., severe jaw ankylosis preventing nutrition), it must be planned in coordination with an FOP specialist.

Emerging and Investigational Approaches

Research into fibrodysplasia ossificans progressiva treatment continues in specialized centers:

  • Activin A inhibitors (e.g., anti-activin A antibodies) to block signals that drive abnormal bone growth.
  • Gene therapy trials aiming to correct the underlying ACVR1 gene mutation.
  • Additional small molecules targeting bone-growth pathways.

While promising, these remain experimental. Participation in a clinical trial often requires evaluation at an FOP-focused research center.

Practical Tips for Living with FOP

Living well with FOP means combining medical therapy with day-to-day strategies:

  • Coordinate care with an FOP specialist or a multidisciplinary team.
  • Keep a flare-up diary: note triggers, timing, and severity.
  • Adapt your environment—use supportive devices, ensure easy access to daily necessities, and minimize fall risk.
  • Educate family, friends, and caregivers about safe handling and emergency plans.

Check Your Symptoms

If you’re unsure whether your aches, swellings, or stiffness could signal a flare-up, consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s a quick way to gather guidance before you talk with your care team.

Talking to Your Doctor

Fibrodysplasia ossificans progressiva treatment continues to evolve. Palovarotene offers new hope, but managing FOP is a lifelong partnership between you and your healthcare providers. Always speak to a doctor about:

  • Any new or worsening symptoms
  • Treatments before starting or stopping medications
  • Side effects that concern you

For anything serious or life threatening—uncontrolled pain, breathing difficulties, or sudden loss of function—seek medical attention immediately. Your doctor knows your history best and will help you choose the safest, most effective path forward.

(References)

  • * Newton MC, Allen PW, Ryan DC. Fibrodysplasia ossificans progressiva. Br J Anaesth. 1990 Feb;64(2):246-50. doi: 10.1093/bja/64.2.246. PMID: 2317429.

  • * Mahboubi S, Glaser DL, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva. Pediatr Radiol. 2001 May;31(5):307-14. doi: 10.1007/s002470100447. PMID: 11379597.

  • * Järvinen TA, Järvinen TL, Kääriäinen M, Kalimo H, Järvinen M. Muscle injuries: biology and treatment. Am J Sports Med. 2005 May;33(5):745-64. doi: 10.1177/0363546505274714. PMID: 15851777.

  • * Järvinen TA, Järvinen TL, Kääriäinen M, Aärimaa V, Vaittinen S, Kalimo H, Järvinen M. Muscle injuries: optimising recovery. Best Pract Res Clin Rheumatol. 2007 Apr;21(2):317-31. doi: 10.1016/j.berh.2006.12.004. PMID: 17512485.

  • * Hoyer-Kuhn H, Schönau E. Pharmacotherapy in Rare Skeletal Diseases. Handb Exp Pharmacol. 2020;261:87-104. doi: 10.1007/164_2019_305. PMID: 32519163.

  • * Hoy SM. Palovarotene: First Approval. Drugs. 2022 Apr;82(6):711-716. doi: 10.1007/s40265-022-01709-z. PMID: 35384641.

  • * Hwang CD, Pagani CA, Nunez JH, Cherief M, Qin Q, Gomez-Salazar M, Kadaikal B, Kang H, Chowdary AR, Patel N, James AW, Levi B. Contemporary perspectives on heterotopic ossification. JCI Insight. 2022 Jul 22;7(14). doi: 10.1172/jci.insight.158996. Epub 2022 Jul 22. PMID: 35866484; PMCID: PMC9431693.

  • * Di Rocco M, Forleo-Neto E, Pignolo RJ, Keen R, Orcel P, Funck-Brentano T, Roux C, Kolta S, Madeo A, Bubbear JS, Tabarkiewicz J, Szczepanek M, Bachiller-Corral J, Cheung AM, Dahir KM, Botman E, Raijmakers PG, Al Mukaddam M, Tile L, Portal-Celhay C, Sarkar N, Hou P, Musser BJ, Boyapati A, Mohammadi K, Mellis SJ, Rankin AJ, Economides AN, Trotter DG, Herman GA, O'Meara SJ, DelGizzi R, Weinreich DM, Yancopoulos GD, Eekhoff EMW, Kaplan FS. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med. 2023 Oct;29(10):2615-2624. doi: 10.1038/s41591-023-02561-8. Epub 2023 Sep 28. PMID: 37770652; PMCID: PMC10579054.

  • * Keen R, Dahir KM, McGinniss J, Sanchez RJ, Mellis S, Economides AN, Di Rocco M, Orcel P, Roux C, Tabarkiewicz J, Bachiller-Corral J, Cheung AM, Al Mukaddam M, Mohammadi K, Gu J, Srinivasan D, Trotter DG, Eekhoff EMW, Kaplan FS, Pignolo RJ. Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial. J Bone Miner Res. 2024 Sep 26;39(10):1486-1492. doi: 10.1093/jbmr/zjae140. PMID: 39216107; PMCID: PMC11425702.

  • * Kuenzler KA, Schwendimann A, Schumann P, Essig H, Ferrari RM. Fibrodysplasia Ossificans Progressiva. Swiss Dent J. 2026 Jul 15;136(2):77-87. doi: 10.61872/sdj-2026-02-07. Epub 2026 Jul 15. PMID: 42455132.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.